Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for OK Biotech Co., Ltd. (4155:TWSE), powered by AI.
OK Biotech Co., Ltd. is currently trading at $15.30. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for OK Biotech Co., Ltd. on Alpha Lenz.
View OK Biotech Co., Ltd.'s valuation metrics on Alpha Lenz.
“OK Biotech Co., Ltd.'s ROE is 3.3%. Explore profitability and growth together.”
Ask for details →OK Biotech Co., Ltd. is a healthcare and biotechnology company that specializes in the development, manufacturing, and distribution of medical devices, particularly focusing on glucose monitoring systems. Its primary purpose is to provide innovative solutions for diabetes management, offering products that help improve the quality of care for diabetic patients. The company's product line includes blood glucose meters, test strips, and continuous glucose monitoring systems, which are essential tools for individuals managing diabetes. OK Biotech impacts both the healthcare and technology sectors by integrating advanced biotechnological research with practical applications for everyday health management. It serves hospitals, healthcare providers, and individual customers by ensuring accessibility to reliable and accurate glucose monitoring technologies. Further, the company emphasizes research and development, often collaborating with global health organizations to stay at the forefront of diabetes management solutions. In the financial market, OK Biotech Co., Ltd. represents a key player in the medical devices and diagnostics space, contributing to the broader healthcare sector's growth. By focusing on diabetic care, the company plays a vital role in addressing one of the most prevalent chronic health conditions globally.
“OK Biotech Co., Ltd.'s ROE is 3.3%. Explore profitability and growth together.”
Ask for details →OK Biotech Co., Ltd. (ticker: 4155) is a company listed on TWSE in the Healthcare sector (Medical Devices).
The current price is 15.3 with a P/E ratio of -x and P/B of -x.
ROE is 3.29% and operating margin is 7.66%. Annual revenue is $1.6B.